Literature DB >> 26525866

A novel class of negative allosteric modulators of NMDA receptor function.

Brooke M Katzman1, Riley E Perszyk2, Hongjie Yuan2, Yesim Altas Tahirovic1, Ayodeji E Sotimehin2, Stephen F Traynelis2, Dennis C Liotta3.   

Abstract

NMDA receptors mediate a slow Ca(2+)-permeable component of excitatory synaptic transmission, and are involved in numerous normal brain functions including learning and memory. NMDA receptor over-activation can lead to cell death and abnormal excitation in ischemia associated with stroke, traumatic brain injury, and epilepsy. We have explored a series of novel noncompetitive allosteric modulators of NMDA receptor function characterized by an iminothiazolidinone ring. Saturating concentrations of these compounds inhibit NMDA receptors to varying maximal extents, raising the possibility that they may attenuate over-activation in pathological situations while preserving some minimal receptor function, which may limit side-effects. The best in class compounds have sub-micromolar IC50 values and show modest preference for GluN2C- and GluN2D-containing receptors.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GluN2; Glutamate; N-Methyl-d-aspartate; Neuroprotection; Noncompetitive antagonist

Mesh:

Substances:

Year:  2015        PMID: 26525866      PMCID: PMC7971076          DOI: 10.1016/j.bmcl.2015.10.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

Review 1.  Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006.

Authors:  Manuel Koller; Stephan Urwyler
Journal:  Expert Opin Ther Pat       Date:  2010-11-08       Impact factor: 6.674

2.  A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.

Authors:  Praseeda Mullasseril; Kasper B Hansen; Katie M Vance; Kevin K Ogden; Hongjie Yuan; Natalie L Kurtkaya; Rose Santangelo; Anna G Orr; Phuong Le; Kimberly M Vellano; Dennis C Liotta; Stephen F Traynelis
Journal:  Nat Commun       Date:  2010-10-05       Impact factor: 14.919

3.  Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.

Authors:  Rose M Santangelo Freel; Kevin K Ogden; Katie L Strong; Alpa Khatri; Kathryn M Chepiga; Henrik S Jensen; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

4.  Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay.

Authors:  J Y Koh; D W Choi
Journal:  J Neurosci Methods       Date:  1987-05       Impact factor: 2.390

Review 5.  Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.

Authors:  G C Palmer
Journal:  Curr Drug Targets       Date:  2001-09       Impact factor: 3.465

Review 6.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

7.  Studies on antidiabetic agents. VI. Asymmetric transformation of (+/-)-5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4- thiazolidinedione(ciglitazone) with optically active 1-phenylethylamines.

Authors:  T Sohda; K Mizuno; Y Kawamatsu
Journal:  Chem Pharm Bull (Tokyo)       Date:  1984-11       Impact factor: 1.645

8.  Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.

Authors:  Kasper B Hansen; Nami Tajima; Rune Risgaard; Riley E Perszyk; Lars Jørgensen; Katie M Vance; Kevin K Ogden; Rasmus P Clausen; Hiro Furukawa; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2013-04-26       Impact factor: 4.436

Review 9.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

10.  Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.

Authors:  Sommer S Zimmerman; Alpa Khatri; Ethel C Garnier-Amblard; Praseeda Mullasseril; Natalie L Kurtkaya; Stefka Gyoneva; Kasper B Hansen; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2014-02-25       Impact factor: 7.446

View more
  4 in total

1.  An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups.

Authors:  Riley Perszyk; Brooke M Katzman; Hirofumi Kusumoto; Steven A Kell; Matthew P Epplin; Yesim A Tahirovic; Rhonda L Moore; David Menaldino; Pieter Burger; Dennis C Liotta; Stephen F Traynelis
Journal:  Elife       Date:  2018-05-24       Impact factor: 8.140

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

3.  The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca2+ Permeability of GluN1/GluN2A N-Methyl-d-Aspartate Receptors.

Authors:  Riley E Perszyk; Zhaoshi Zheng; Tue G Banke; Jing Zhang; Lingling Xie; Miranda J McDaniel; Brooke M Katzman; Stephen C Pelly; Hongjie Yuan; Dennis C Liotta; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2021-03-09       Impact factor: 4.436

Review 4.  Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Authors:  Erica S Burnell; Mark Irvine; Guangyu Fang; Kiran Sapkota; David E Jane; Daniel T Monaghan
Journal:  J Med Chem       Date:  2018-03-05       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.